000			01940 a2200601 4500
005			20250516045136.0
264		0	_c20110916
008			201109s 0 0 eng d
022			_a1532-1827
024	7		_a10.1038/bjc.2011.183 _2doi
040			_aNLM _beng _cNLM
100	1		_aO'Day, S
245	0	0	_aA randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. _h[electronic resource]
260			_bBritish journal of cancer _cJul 2011
300			_a346-52 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aDacarbazine _xadministration & dosage
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aIntegrin alphaV _ximmunology
650	0	4	_aMale
650	0	4	_aMelanoma _xdrug therapy
650	0	4	_aMiddle Aged
650	0	4	_aSkin Neoplasms _xdrug therapy
650	0	4	_aUveitis _xchemically induced
700	1		_aPavlick, A
700	1		_aLoquai, C
700	1		_aLawson, D
700	1		_aGutzmer, R
700	1		_aRichards, J
700	1		_aSchadendorf, D
700	1		_aThompson, J A
700	1		_aGonzalez, R
700	1		_aTrefzer, U
700	1		_aMohr, P
700	1		_aOttensmeier, C
700	1		_aChao, D
700	1		_aZhong, B
700	1		_ade Boer, C J
700	1		_aUhlar, C
700	1		_aMarshall, D
700	1		_aGore, M E
700	1		_aLang, Z
700	1		_aHait, W
700	1		_aHo, P
773	0		_tBritish journal of cancer _gvol. 105 _gno. 3 _gp. 346-52
856	4	0	_uhttps://doi.org/10.1038/bjc.2011.183 _zAvailable from publisher's website
999			_c21001363 _d21001363